文献速递肥胖与代谢综合征糖尿病

二氮嗪介导的胰岛素抑制对非糖尿病肥胖男性糖脂代谢的影响

Effects of Diazoxide-Mediated Insulin Suppression on Glucose and Lipid Metabolism in Nondiabetic Obese Men.
PubMed 文献 · J Clin Endocrinol Metab · 2018-01-01

这项双盲、安慰剂对照的6个月试验在体重指数30至37.5 kg/m2的非糖尿病肥胖男性中,联合热量限制、标准化运动方案与二氮嗪或安慰剂剂量递增,评估二氮嗪对糖脂代谢的影响。二氮嗪平均最大耐受剂量为422±44 mg/d(范围200至700 mg/d),剂量限制性事件为水肿(n=11)、高血糖(n=6)和恶心(n=2)。减量至无临床副作用水平后,二氮嗪组空腹胰岛素降幅显著大于安慰剂组(-72.3±3.5% vs -23.0±12.6%;P<0.001),血压和血脂显著改善,但伴随血糖轻度升高(0.6±0.2 mmol/L vs -0.1±0.1 mmol/L;P=0.04),糖化血红蛋白变化两组间无显著差异(0.2±0.1% vs 0.0±0.1%;P=0.17)。

要点

  • 二氮嗪平均最大耐受剂量422±44 mg/d(范围200至700 mg/d),剂量限制性事件为水肿、高血糖和恶心。
  • 减量至无临床副作用后,二氮嗪组空腹胰岛素降幅-72.3±3.5%,显著大于安慰剂组-23.0±12.6%(P<0.001)。
  • 二氮嗪组血糖轻度升高0.6±0.2 mmol/L,安慰剂组为-0.1±0.1 mmol/L(P=0.04);糖化血红蛋白变化两组间无显著差异(P=0.17)。

核心结论

  • 在非糖尿病肥胖男性中,胰岛素水平可降低达70%而不出现主要代谢副作用。
  • 最大耐受剂量的明显个体间差异表明二氮嗪剂量滴定需要个体化。

研究设计与样本

  • 双盲、安慰剂对照、为期6个月的试验,纳入体重指数30至37.5 kg/m2的非糖尿病肥胖男性。
  • 受试者接受热量限制、标准化运动方案联合二氮嗪或安慰剂剂量递增治疗。

主要发现

  • 二氮嗪平均最大耐受剂量为422±44 mg/d(范围200至700 mg/d)。
  • 剂量限制性事件为水肿(n=11)、高血糖(n=6)和恶心(n=2)。
  • 减量至无临床副作用水平后,二氮嗪组空腹胰岛素降幅-72.3±3.5%,安慰剂组-23.0±12.6%(P<0.001)。
  • 二氮嗪组血糖升高0.6±0.2 mmol/L,安慰剂组为-0.1±0.1 mmol/L(P=0.04)。
  • 二氮嗪组糖化血红蛋白升高0.2±0.1%,安慰剂组为0.0±0.1%(P=0.17)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: It has been suggested that stimulation of lipolysis by diazoxide (DZX)-mediated insulin suppression may be useful in treating obesity. However, the optimal dose to promote lipolysis without causing hyperglycemia is unknown. OBJECTIVE: To assess the effects of DZX in nondiabetic obese men on lipid and glucose metabolism. DESIGN: Double-blind, placebo (PL)-controlled, 6-month trial in men with a body mass index of 30 to 37.5 kg/m2 treated with a combination of caloric restriction, a standardized exercise program, and DZX or PL dose escalation. RESULTS: The mean maximal tolerated dose of DZX was 422 ± 44 mg/d (range, 200 to 700 mg/d). Dose-limiting events were edema (n = 11), hyperglycemia (n = 6), and nausea (n = 2). After dose reduction to a level free of clinical side effects, DZX treatment was associated with a markedly greater decrease in fasting insulin levels than PL (-72.3 ± 3.5% vs -23.0 ± 12.6%; P < 0.001) and a significant improvement of blood pressure and plasma lipid levels. The decline in insulin levels occurred at the cost of a small increase in plasma glucose (0.6 ± 0.2 mmol/L vs -0.1 ± 0.1 mmol/L; P = 0.04) and hemoglobin A1C (0.2 ± 0.1% vs 0.0 ± 0.1%; P = 0.17). CONCLUSION: In nondiabetic obese men, insulin levels can be reduced up to 70% without major metabolic side effects. The marked intersubject variation in maximal tolerated dose indicates that DZX dose titration needs to be individualized.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Loves S, van Groningen L, Filius M, et al. Effects of Diazoxide-Mediated Insulin Suppression on Glucose and Lipid Metabolism in Nondiabetic Obese Men. J Clin Endocrinol Metab. 2018. PMID: 29618011. doi:10.1210/jc.2018-00161

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。